Lenangio 5mg Capsule (Lenalidomide)

Lenangio 5mg Capsule contains lenalidomide 5 mg, an immunomodulatory anticancer medicine derived from thalidomide. It binds cereblon and changes the degradation of transcription factors involved in malignant plasma/B-cell survival and immune signaling. It is widely used in multiple myeloma and selected myelodysplastic syndromes and lymphomas. Lenalidomide 5mg capsules can cause severe embryo-fetal toxicity, neutropenia, thrombocytopenia, and venous/arterial thrombosis. The 5 mg capsule is a strength; dose and cycle depend strongly on indication and kidney function.

In multiple myeloma, the lenalidomide 5mg capsule is used with dexamethasone and other agents in newly diagnosed or relapsed disease and as maintenance after autologous stem-cell transplantation. In transfusion-dependent anemia due to low/intermediate-1-risk MDS with deletion 5q, 5 mg is a standard starting dose under the label. It is also used with rituximab for follicular lymphoma and marginal-zone lymphoma in selected settings.

Lenalidomide 5mg Capsule binds cereblon, altering the ubiquitin ligase complex and promoting degradation of IKZF1/IKZF3. This has direct antimyeloma effects and enhances T-cell/NK-cell immune activity.

FIRST/MM-020: Lenalidomide-dexamethasone established an effective backbone for transplant-ineligible newly diagnosed myeloma.

CALGB 100104/IFM maintenance studies: Lenalidomide 5mg capsule maintenance after autologous transplant prolonged progression-free survival.

MDS del(5q) studies: Lenalidomide 5mg Capsule produced high rates of transfusion independence and cytogenetic response in selected del(5q) MDS.

Just like any other medication, the Lenangio 5mg Capsule is also associated with some side effects. Most of the side effects are minor and usually go away within some time. Here are some of the symptoms, including:

Common side effects

• Neutropenia
  
• Thrombocytopenia
  
• Anemia
  
• Fatigue
  
• Diarrhea/constipation
  
• Rash
  
• Muscle cramps
  

Serious side effects

• Severe embryo-fetal toxicity
  
• Venous/arterial thrombosis
  
• Serious infection
  
• Severe skin reactions
  
• Tumor lysis/tumour flare in lymphoma
  
• Secondary primary malignancies

Important: Dose and regimen must be prescribed by the treating specialist. Capsule/vial strength is not necessarily the patient dose. Do not start, stop, split, combine, or substitute treatment based on website information.

Follow the specific regimen for missed doses; do not double. Because some labels use a time threshold for taking a late dose, follow the pack leaflet or contact the hematology team.

• CBC frequently during early cycles
  
• Renal function
  
• Pregnancy testing/compliance
  
• Thrombosis symptoms
  
• Myeloma markers/disease response
  
• Thyroid function when clinically indicated
  

• Current lenalidomide 10mg Capsule prescribing information (Revlimid/reference). https://packageinserts.bms.com/pi/pi_revlimid.pdf​
  
• Benboubker L, et al. FIRST/MM-020. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa1402551​
  
• McCarthy PL, et al. Lenalidomide maintenance. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa1114083​
  
• Current NCCN multiple-myeloma/MDS/lymphoma guidelines. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445​
  
• ScienceDirect. Lenalidomide 10mg Capsule. https://www.sciencedirect.com/topics/medicine-and-dentistry/lenalidomide​